Milademetan in Advanced Solid Tumors with <i>MDM2</i> Amplification and Wild-type <i>TP53</i>: Preclinical and Phase II Clinical Trial Results

Ecaterina E. Dumbrava, Christopher T. Chen|Clinical Cancer Research|2025

Cited by 7